Department of Angiology, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria, Europe.
Catheter Cardiovasc Interv. 2009 Dec 1;74(7):1090-5. doi: 10.1002/ccd.22128.
Recent randomized trials investigating stent implantation compared with balloon angioplasty for treatment of superficial femoral artery (SFA) disease have given divergent results in short (mean 5 cm) and intermediate (mean 10 cm) lesions. We reinvestigated whether primary nitinol stenting is associated with a morphologic and clinical benefit when compared with percutaneous transluminal angioplasty with optional stenting (PTA) in intermediate-length lesions.
We randomly assigned 73 patients with severe claudication or chronic limb ischemia and average 8 cm long (range 3-20 cm) SFA stenosis or occlusion to primary stent implantation (n = 34) or PTA (n = 39). Restenosis >50% and clinical outcome were assessed at 3, 6, and 12 months postintervention.
Average length of the treated segments was 98 + or - 54 mm and 71 + or - 43 mm in the stent and PTA groups (P = 0.011), respectively. In the PTA group, secondary stenting was performed in 10 of 39 patients (26%) due to a suboptimal result after balloon dilation. Restenosis rates in the stent and PTA groups were 21.9% versus 55.6% (P = 0.005) at 6 months by CT-angiography, and 2.9% versus 18.9% (P = 0.033), 18.2% versus 50.0% (P = 0.006), and 34.4% versus 61.1% (P = 0.028) at 3, 6, and 12 months by sonography, respectively. Clinically, patients in the stent group reported a significantly higher maximum walking capacity compared with the PTA group at 6 and 12 months.
In this randomized multicenter trial, primary stenting with a self-expanding nitinol stent for treatment of intermediate length SFA disease resulted morphologically and clinically superior midterm results compared with balloon angioplasty with optional secondary stenting.
最近的随机临床试验比较了支架植入术与球囊血管成形术治疗股浅动脉(SFA)疾病,在短(平均 5cm)和中等长度(平均 10cm)病变中得出了不同的结果。我们重新研究了在中等长度病变中,与经皮腔内血管成形术伴选择性支架置入术(PTA)相比,原发性镍钛诺支架置入术是否与形态学和临床获益相关。
我们随机分配了 73 名有严重跛行或慢性肢体缺血且 SFA 狭窄或闭塞平均长度为 8cm(范围 3-20cm)的患者,分别进行原发性支架植入术(n=34)或 PTA(n=39)。在介入治疗后 3、6 和 12 个月评估再狭窄>50%和临床结果。
治疗节段的平均长度分别为支架组 98+/-54mm 和 PTA 组 71+/-43mm(P=0.011)。在 PTA 组中,由于球囊扩张后效果不理想,10 例 39 例患者(26%)进行了二次支架置入。支架组和 PTA 组的 6 个月 CT 血管造影再狭窄率分别为 21.9%和 55.6%(P=0.005),6 个月超声分别为 2.9%和 18.9%(P=0.033)、18.2%和 50.0%(P=0.006)、34.4%和 61.1%(P=0.028)。在临床方面,支架组患者在 6 个月和 12 个月时报告的最大步行能力明显高于 PTA 组。
在这项随机多中心试验中,与球囊血管成形术伴选择性二次支架置入术相比,原发性自膨式镍钛诺支架置入术治疗中等长度 SFA 疾病在形态学和临床方面均具有中期优势。